D
The startup develops a sustained intranasal drug delivery system that utilizes active resorbable scaffolds and asymmetric balloons to treat conditions such as chronic sinusitis, allergic rhinitis, and intranasal bleeding. This technology provides an alternative to daily medication, enabling remote patient monitoring and improved management of ENT conditions.
Updated 3 months ago
Funding
$6.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a sustained intranasal drug delivery system that utilizes active resorbable scaffolds and asymmetric balloons to treat conditions such as chronic sinusitis, allergic rhinitis, and intranasal bleeding. This technology provides an alternative to daily medication, enabling remote patient monitoring and improved management of ENT conditions.